Tropicamide is an antimuscarinic eye drop used in ophthalmic care to dilate the pupil (mydriasis) and temporarily paralyze the eye’s focusing muscle (cycloplegia). It is supplied as a 1 % ophthalmic solution packaged in a sterile bottle. In Hong Kong, Tropicamide is classified as a prescription-only medication under the Pharmacy and Poisons Ordinance. Various manufacturers market the drug under brand names such as Mydriacyl (Novartis) and Cyclogyl (Alcon).
Tropicamide blocks muscarinic acetylcholine receptors located in the sphincter pupillae muscle of the iris and the ciliary body. By preventing the action of acetylcholine, the iris muscle relaxes, causing the pupil to enlarge. Simultaneously, inhibition of the ciliary muscle reduces its ability to change lens shape, resulting in cycloplegia. The drug’s onset of action is typically within 15-30 minutes, with peak dilation occurring around 30-45 minutes and effects lasting 4-6 hours. Its ocular bioavailability is high because the solution is applied directly to the eye surface, and systemic absorption is minimal.
These indications are approved by the Hong Kong Department of Health for the 1 % ophthalmic solution of Tropicamide.
This article provides educational information about Tropicamide and is not a substitute for professional medical advice. Treatment decisions, including the use of Tropicamide for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Tropicamide is a topical ophthalmic solution and contains no metallic or prohibited substances. Passengers should declare any liquid medication if it exceeds the standard carry-on volume limit, but the drops themselves do not trigger security alerts.
Commercial bottles of Tropicamide 1 % are typically amber-colored to protect from light. The label often displays the brand name (e.g., Mydriacyl) and the concentration. Some manufacturers imprint a batch number and expiration date on the cap or label for traceability.
Tropicamide is not listed as a prohibited substance by major anti-doping agencies because it is a locally administered ophthalmic agent with negligible systemic absorption. Nevertheless, athletes should disclose any medication use to their governing bodies.
Contact lenses should be removed before instilling Tropicamide to avoid trapping the solution between the lens and the cornea. Re-insert lenses after the medication has been absorbed, usually a few minutes post-administration.
Tropicamide is an antimuscarinic agent causing both mydriasis and cycloplegia, whereas phenylephrine is an adrenergic agonist that dilates the pupil without affecting accommodation. Tropicamide typically provides a faster onset and shorter duration of cycloplegia compared with other agents.
Standard room temperature (15-30 °C) is appropriate. In the humid subtropical climate of Hong Kong, keep the bottle in a dry place away from direct sunlight to maintain solution integrity.
Yes, but ensure the quantity complies with the destination country’s import regulations for prescription medicines. Carry the original prescription label and a copy of the prescribing doctor's note to avoid customs complications.
If leakage occurs, discard the contents safely, wash the surrounding area with soap and water, and replace the medication with a new, intact bottle. Leaking containers may compromise sterility and dosage accuracy.
Both Tropicamide and certain antihistamine eye drops possess anticholinergic properties; concurrent use may intensify pupil dilation and dry-eye symptoms. Patients should inform their ophthalmologist before combining such products.
A 1 % concentration offers an optimal balance between effective mydriasis and a low risk of prolonged cycloplegia or systemic absorption. Higher concentrations are generally unnecessary for routine diagnostic purposes and may increase adverse-event potential.
